ABCB1 and cancer: The increased expression of ABCB1 in cancer cells enhances the efflux of various structurally and mechanistically different anticancer drugs, such as paclitaxel, docetaxel, vincristine, doxorubicin, imatinib, and nilotinib, leading to decreased intracellular drug levels and subsequent chemoresistance.